Coulter Partners places Global Head, Regulatory Affairs for Celyad.

Coulter Partners was delighted to partner with Celyad secure the appointment of Dr. Bianca Krafft as their Global Head of Regulatory Affairs. Listed on Nasdaq (CYAD) and Euronext (CYAD), Celyad is a clinical-stage biopharmaceutical company headquartered in Belgium, with operations in Boston, MA. Celyad utilizes its expertise in cell engineering to target cancers, both haematological and solid-tumours, with proprietary CAR-T approaches.

“Bianca brings a wealth of experience gained over 13 years in leading Global Regulatory Affair roles spanning discovery to life-cycle management and due diligence, with an emphasis on heme/onc. She will be an invaluable addition to the Celyad team as they develop and execute on a regulatory pathway for these critical immunotherapies, and we wish her every success in her new role,” comments Christopher Palatucci, PhD, Client Partner at Coulter Partners.

In addition to her magna cum laude PhD, with a focus on expression and analysis of GPCRs, Dr. Krafft obtained two Masters degrees, one in Biotechnology and a second in Drug Regulatory Affairs. She has had extensive industry interactions with regulatory agencies across the globe, and gained valuable experience building and growing teams at leading pharmaceutical companies, both big and small, such as Gruenenthal, HGS, and Bayer.

Dr. Krafft will be based in Celyad’s Boston offices, and will lead the company’s regulatory programs as well as building out the company’s clinical leadership in the US.